TOKYO – Six months after winning PMDA approval, Eli Lilly Japan and Nippon Boehringer Ingelheim (NBI) recently disclosed plans to launch the first insulin glargine biosimilar in Japan, a market in which biosimilars are advancing, albeit slowly.